title: Beta-asarone protects against MPTP-induced Parkinson's disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression.
abstract: OBJECTIVE
  Numerous long non-coding RNAs (lncRNA) have been identified in neurodegenerative disorders including Parkinson's disease (PD). Emerging evidence demonstrates that β-asarone functions as neuroprotective effects in both in vitro and in vivo models. However, the role of β-asarone and its potential mechanism in PD remain not completely clear.
  
  
  METHODS
  MPTP-induced PD mouse model and SH-SY5Y cells subjected to MPP+ as its in vitro model were used to evaluate the effects of β-asarone on PD. LncRNA MALAT1 and α-synuclein expression were determined by real-time PCR and western blot methods.
  
  
  RESULTS
  β-Asarone significantly increased the TH+ cells number and decreased the expression levels of MALAT1 and α-synuclein in midbrain tissue of PD mice. RNA pull-down and immunoprecipitation assays confirmed that MALAT1 associated with α-synuclein, leading to the increased stability of α-synuclein and its expression in SH-SY5Y cells. β-asarone elevated the viability of cells exposed to MPP+. Either overexpressed MALAT1 or α-synuclein could canceled the protective effect of β-asarone on cell viability. In PD mice, pcDNA-MALAT1 also decreased the TH+ cells number and increased the α-synuclein expression in PD mice with treatment of β-asarone.
  
  
  CONCLUSIONS
  β-Asarone functions as a neuroprotective effect in both in vivo and in vitro models of PD via regulating MALAT1 and α-synuclein expression.
authors.affiliation: Department of Internal Neurology, Huaihe Hospital of Henan University, Kaifeng 475000, China.
authors.forename: Qi-Shun
authors.initials: QS
authors.lastname: Zhang
authors.affiliation: Department of Internal Neurology, Huaihe Hospital of Henan University, Kaifeng 475000, China. Electronic address: wzhdyl0526@163.com.
authors.forename: Zhao-Hui
authors.initials: ZH
authors.lastname: Wang
authors.affiliation: Department of Internal Neurology, Huaihe Hospital of Henan University, Kaifeng 475000, China.
authors.forename: Jian-Lei
authors.initials: JL
authors.lastname: Zhang
authors.affiliation: Department of Ultrasound, Kaifeng Maternity Hospital, Kaifeng 475000, China.
authors.forename: Yan-Li
authors.initials: YL
authors.lastname: Duan
authors.affiliation: Department of Internal Neurology, Huaihe Hospital of Henan University, Kaifeng 475000, China.
authors.forename: Guo-Fei
authors.initials: GF
authors.lastname: Li
authors.affiliation: Department of Internal Neurology, Huaihe Hospital of Henan University, Kaifeng 475000, China.
authors.forename: Dong-Lin
authors.initials: DL
authors.lastname: Zheng
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000081248:Allylbenzene Derivatives; D000818:Animals; D000840:Anisoles / Q000494:pharmacology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D008810:Mice, Inbred C57BL; D009474:Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D062085:RNA, Long Noncoding / Q000235:genetics* / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D051844:alpha-Synuclein / Q000378:metabolism*
chemical_list: D000081248:Allylbenzene Derivatives; D000840:Anisoles; C557041:MALAT1 long non-coding RNA, human; D018696:Neuroprotective Agents; D062085:RNA, Long Noncoding; D051844:alpha-Synuclein; C012195:asarone; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase
keywords: Long non-coding RNA; Parkinson’s disease; α-Synuclein; β-Asarone